Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men

Igarashi M, Nakagawa-Nagahama Y, Miura M, Kashiwabara K, Yaku K, Sawada M, et al. | npj Aging | 2022 | Evidence: moderate

View on PubMed → | DOI | Publisher

Plain-language summary

Published 2022 in npj Aging, this work by Igarashi M and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

12-week 250 mg/day NMN in healthy older men raised whole-blood NAD+ and altered muscle function
Walking speed and grip strength improvements reported with morning dosing
Population: healthy older Japanese men (not mixed-sex)

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the moderate end of the evidence spectrum. Moderate-tier evidence usually means a small human trial or a well-designed mouse study; helpful for hypothesis-building but not for hard recommendations. Findings here are most directly relevant to benefits decisions, with secondary relevance to dosage and safety. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

← Back to research index